Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT)

•Efficacy and safety of rivaroxaban in extreme elderly patients (age >80 years).•Body weight and renal function were significantly lower in the elderly.•Elderly patients had higher baseline risk factors for thrombosis (CHADS2 score).•Incidence of cerebral infarction by rivaroxaban was not increas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiology 2018-02, Vol.71 (2), p.197-201
Hauptverfasser: Bando, Shigenobu, Nishikado, Akiyoshi, Hiura, Norikazu, Ikeda, Shuntaro, Kakutani, Akiyoshi, Yamamoto, Katsuhito, Kaname, Noriyoshi, Fukatani, Masahiko, Takagi, Yuichiro, Yukiiri, Kazushi, Fukuda, Yamato, Nakaya, Yutaka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Efficacy and safety of rivaroxaban in extreme elderly patients (age >80 years).•Body weight and renal function were significantly lower in the elderly.•Elderly patients had higher baseline risk factors for thrombosis (CHADS2 score).•Incidence of cerebral infarction by rivaroxaban was not increased in the elderly.•Recommended dose of rivaroxaban is useful also in the elderly patients. The Shikoku Rivaroxaban Registry Trial (SRRT) is a retrospective survey of the use of rivaroxaban for stroke prevention in elderly patients in Shikoku, Japan. The SRRT enrolled 1339 patients from 8 hospitals. Patients were divided into two groups according to their age, the extreme elderly group (453 patients aged ≧80 years) and the control group (886 patients aged
ISSN:0914-5087
1876-4738
DOI:10.1016/j.jjcc.2017.08.005